Minocycline Hydrochloride

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally advanced cutaneous squamous cell carcinoma MIAMI, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the third quarter ended September 30, 2024. Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “We are thrilled to have received U.S. Food and Drug Administration (“FDA”) approval for Emrosi™, a potential best-in-class treatment for inflammatory lesions of rosacea in adults, which is a tremendous milestone for Fortress and our partner company, Journey Medical Corporation (“Journey Medical”). This marks the first FDA approval across the Fortress portfolio, and demonstrates our ability to successfully in-license a clinical stage program and develop it through commercialization. We could achieve up to two more U.S. FDA approvals in the next nine months, and our next anticipated PDUFA goal date is December 28, 2024, for cosibelimab, an anti-PD-L1 antibody, for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (“cSCC”). We have an exciting late-stage pipeline with many upcoming value creation opportunities, and we are focused on attaining our long-term strategy of building shareholder value, while bringing innovative treatment options to patients with unmet medical needs.” Recent Corporate Highlights1: Regulatory Updates In November 2024, the FDA approved Emrosi (Minocycline Hydrochloride Extended-Release Capsules, 40mg), also known as DFD-29. Emrosi has the potential to be the new treatment paradigm for the millions of patients suffering from inflammatory lesions of rosacea. The treatment is expected to launch late in the first quarter or early in the second quarter of 2025 by our partner company, Journey Medical (Nasdaq: DERM).In July 2024, the FDA accepted the Biologics License Application (“BLA”) resubmission for cosibelimab, our investigational anti-PD-L1 antibody, as a treatment for patients with metastatic or locally advanced cSCC who are not candidates for curative surgery or radiation and set a PDUFA goal date of December 28, 2024. Cosibelimab is currently in development at our partner company, Checkpoint Therapeutics (Nasdaq: CKPT) (“Checkpoint”).In December 2023, we completed the asset transfer of CUTX-101 (copper histidinate for Menkes disease) to Sentynl Therapeutics (“Sentynl”), a wholly owned subsidiary of Zydus Lifesciences Ltd. Sentynl completed the rolling submission of the New Drug Application for CUTX-101 in the fourth quarter of 2024. Cyprium Therapeutics (“Cyprium”), our subsidiary company that developed CUTX-101, will retain 100% ownership over any FDA priority review voucher that may be issued at NDA approval for CUTX-101. Clinical Updates In October 2024, clinical data were presented at the 44th Fall Clinical Dermatology Conference assessing the dermal and systemic pharmacokinetics of Emrosi versus oral doxycycline 40 mg capsules (Oracea®) in healthy subjects. With its extended-release formulation, Emrosi provides higher dermal concentration than doxycycline from day 1 onward at a similar dose, expected to translate into a clinically meaningful impact for treating patients with rosacea, and as demonstrated in Emrosi’s Phase 3 clinical trials.In September 2024, we presented longer-term data from our pivotal trial of cosibelimab in locally advanced and metastatic cSCC during the European Society for Medical Oncology (“ESMO”) Congress 2024. The longer-term results for cosibelimab demonstrate a deepening of response over time, with higher objective response and complete response rates than initially observed at the primary analyses. Other Updates In July 2024, we announced a collaboration to explore the combined therapeutic potential of cosibelimab with GC Cell’s Immuncell-LC, an innovative autologous Cytokine Induced Killer (“CIK”) T cell therapy composed of cytotoxic T lymphocytes and natural killer T cells.Also in July 2024, our majority owned and controlled subsidiary company, Urica Therapeutics (“Urica”), entered into an asset purchase agreement, royalty agreement and related agreements with Crystalys Therapeutics (“Crystalys”). Urica transferred rights to dotinurad, its URAT1 inhibitor product candidate in development for the treatment of gout, and related intellectual property, licenses and agreements to Crystalys. In return, Crystalys issued to Urica shares of its common stock equal to 35% of Crystalys’ outstanding equity and granted Urica a securitized 3% royalty on future net sales of dotinurad. Commercial Product Updates Journey Medical’s net product revenues for the third quarter ended September 30, 2024 were $14.6 million, compared to net product revenues of $14.9 million for the second quarter ended June 30, 2024. General Corporate: In July 2024, Checkpoint raised $12 million in a registered direct offering priced at-the-market under Nasdaq rules.In July 2024, Fortress’ Board of Directors paused the payment of dividends on the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) until further notice. The Company believes pausing the dividend is in the best interest of the Company and its stakeholders to maintain financial flexibility ahead of potentially significant inflection points. Dividends on the Series A Preferred Stock accrue in accordance with their terms; the pausing of these dividends will defer approximately $0.7 million in cash dividend payments each month. The Board intends to revisit its decision regarding the monthly dividend regularly and will assess the profitability and cash flow of the Company to determine whether and when the suspension should be lifted.Also in July 2024, Fortress reduced its total debt by entering into a new loan agreement maturing in July 2027 with funds managed by Oaktree Capital Management, L.P. (“Oaktree”), a leading global investment firm. The Company received an initial tranche of $35 million and is eligible to draw an additional $15 million with Oaktree’s consent. In connection with the new loan agreement, the Company repaid its prior term loan with Oaktree of $50 million resulting in an outstanding debt reduction of approximately $15 million of debt excluding accrued interest and prepayment fees.In September 2024, Fortress raised $8 million in a registered direct offering and concurrent private placements.In October 2024, Mustang Bio raised $4 million in gross proceeds from the exercise of existing warrants.In November 2024, Checkpoint received $9.2 million in gross proceeds through the exercise of existing warrants. Financial Results: As of September 30, 2024, Fortress’ consolidated cash and cash equivalents totaled $58.9 million, compared to $76.2 million as of June 30, 2024, and compared to $80.9 million as of December 31, 2023, a decrease of $17.3 million during the quarter and a decrease of $22.0 million year-to-date.Fortress’ consolidated cash and cash equivalents, totaling $58.9 million as of September 30, 2024, includes $25.6 million attributable to Fortress and the private subsidiaries, $2.6 million attributable to Avenue, $4.7 million attributable to Checkpoint, $3.5 million attributable to Mustang Bio and $22.5 million attributable to Journey Medical. Fortress’ consolidated cash and cash equivalents totaled $80.9 million as of December 31, 2023, which included $40.6 million attributable to Fortress and private subsidiaries, $1.8 million attributable to Avenue, $4.9 million attributable to Checkpoint, $6.2 million attributable to Mustang Bio and $27.4 million attributable to Journey Medical. Fortress’ consolidated net revenue totaled $14.6 million for the third quarter ended September 30, 2024, all of which was generated from our marketed dermatology products. This compares to consolidated revenue totaling $34.8 million for the third quarter of 2023, which included $15.3 million in revenue generated from our marketed dermatology products and an upfront license agreement payment of $19 million.Consolidated research and development expenses including license acquisitions totaled $9.4 million for the third quarter ended September 30, 2024, compared to $20.3 million for the third quarter ended September 30, 2023.Consolidated selling, general and administrative costs were $22.0 million for the third quarter ended September 30, 2024, compared to $21.7 million for the third quarter ended September 30, 2023.Consolidated net loss attributable to common stockholders was $(15.0) million, or $(0.76) per share, for the third quarter ended September 30, 2024, compared to net loss attributable to common stockholders of $(7.1) million, or $(0.94) per share for the third quarter ended September 30, 2023. About Fortress Biotech Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has seven marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit www.fortressbiotech.com. Forward-Looking StatementsStatements in this press release that are not descriptions of historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. The words “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “potential,” “predicts,” “should,” or “will” or the negative of these terms or other comparable terminology are generally intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated include risks relating to: our growth strategy, financing and strategic agreements and relationships; our need for substantial additional funds and uncertainties relating to financings; our ability to identify, acquire, close and integrate product candidates successfully and on a timely basis; our ability to attract, integrate and retain key personnel; the early stage of products under development; the results of research and development activities; uncertainties relating to preclinical and clinical testing; our ability to obtain regulatory approval for products under development; our ability to successfully commercialize products for which we receive regulatory approval or receive royalties or other distributions from third parties; our ability to secure and maintain third-party manufacturing, marketing and distribution of our and our partner companies’ products and product candidates; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as may be required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. The information contained herein is intended to be reviewed in its totality, and any stipulations, conditions or provisos that apply to a given piece of information in one part of this press release should be read as applying mutatis mutandis to every other instance of such information appearing herein. Company Contact:Jaclyn JaffeFortress Biotech, Inc.(781) 652-4500ir@fortressbiotech.com Media Relations Contact:Tony Plohoros6 Degrees(908) 591-2839tplohoros@6degreespr.com FORTRESS BIOTECH, INC. AND SUBSIDIARIESUnaudited Condensed Consolidated Balance Sheets ($ in thousands except for share and per share amounts) September 30, December 31, 2024 2023 ASSETS Current assets Cash and cash equivalents $58,853 $80,927 Accounts receivable, net 10,671 15,222 Inventory 11,788 10,206 Other receivables - related party 174 167 Prepaid expenses and other current assets 2,583 10,500 Assets held for sale 2,209 — Total current assets 86,278 117,022 Property, plant and equipment, net 3,403 6,505 Operating lease right-of-use asset, net 14,152 16,990 Restricted cash 2,063 2,438 Intangible assets, net 17,844 20,287 Other assets 3,345 4,284 Total assets $ 127,085 $ 167,526 LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) Current liabilities Accounts payable and accrued expenses $64,499 $73,562 Income taxes payable 850 843 Common stock warrant liabilities 154 886 Operating lease liabilities, short-term 2,514 2,523 Partner company convertible preferred shares, short-term, net — 3,931 Partner company installment payments - licenses, short-term 1,250 3,000 Other short-term liabilities 1,038 163 Total current liabilities 70,305 84,908 Notes payable, long-term, net 52,473 60,856 Operating lease liabilities, long-term 15,292 18,282 Other long-term liabilities 1,753 1,893 Total liabilities 139,823 165,939 Commitments and contingencies Stockholders’ equity (deficit) Cumulative redeemable perpetual preferred stock, $0.001 par value, 15,000,000 authorized, 5,000,000 designated Series A shares, 3,427,138 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively, liquidation value of $25.00 per share 3 3 Common stock, $0.001 par value, 200,000,000 shares authorized, 27,584,600 and 15,093,053 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 28 15 Additional paid-in-capital 755,229 717,396 Accumulated deficit (734,102) (694,870)Total stockholders' equity attributed to the Company 21,158 22,544 Non-controlling interests (33,896) (20,957)Total stockholders' equity (deficit) (12,738) 1,587 Total liabilities and stockholders' equity (deficit) $ 127,085 $ 167,526 FORTRESS BIOTECH, INC. AND SUBSIDIARIESUnaudited Condensed Consolidated Statements of Operations($ in thousands except for share and per share amounts) Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Revenue Product revenue, net $14,629 $15,279 $42,514 $44,405 Collaboration revenue — 182 — 546 Revenue - related party — 31 41 97 Other revenue — 19,260 — 19,519 Net revenue 14,629 34,752 42,555 64,567 Operating expenses Cost of goods sold - product revenue 5,285 6,429 18,642 20,645 Research and development 9,446 20,288 46,941 87,702 Research and development - licenses acquired — 60 — 4,293 Selling, general and administrative 21,993 21,733 60,867 71,512 Asset impairment — — 2,649 3,143 Total operating expenses 36,724 48,510 129,099 187,295 Loss from operations (22,095) (13,758) (86,544) (122,728) Other income (expense) Interest income 589 547 2,157 2,296 Interest expense and financing fee (6,209) (2,534) (10,933) (13,255)Gain (loss) on common stock warrant liabilities 19 4,542 (578) 10,708 Other income (expense) 1,071 620 1,334 (2,049)Total other income (expense) (4,530) 3,175 (8,020) (2,300)Loss before income tax expense (26,625) (10,583) (94,564) (125,028) Income tax expense (refund) 69 141 (24) 142 Net loss (26,694) (10,724) (94,540) (125,170) Net loss attributable to non-controlling interests 13,827 5,679 55,308 73,812 Net loss attributable to Fortress $ (12,867) $ (5,045) $ (39,232) $ (51,358) Preferred A dividends declared and paid and/or cumulated, and Fortress' share of subsidiary deemed dividends (2,173) (2,008) (7,006) (6,024)Net loss attributable to common stockholders $ (15,040) $ (7,053) $ (46,238) $ (57,382) Net loss per common share attributable to common stockholders - basic and diluted $(0.76) $(0.94) $(2.43) $(7.94) Weighted average common shares outstanding - basic and diluted 19,697,290 7,498,653 19,041,590 7,231,004 1 The development programs depicted in this press release include product candidates in development at Fortress, at Fortress’ private subsidiaries (referred to herein as “subsidiaries”), at Fortress’ public subsidiaries (referred to herein as “partner companies”) and at entities with whom one of the foregoing parties has a significant business relationship, such as an exclusive license or an ongoing product-related payment obligation (such entities referred to herein as “partners”). The words “we”, “us” and “our” may refer to Fortress individually, to one or more of our subsidiaries and/or partner companies, or to all such entities as a group, as dictated by context.

The US Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi (minocycline hydrochloride extended release capsules 40mg) to treat inflammatory lesions of rosacea in adults. Affecting more than 16 million people in the US, rosacea is a long-term inflammatory skin condition that causes deep facial redness, acne-like inflammatory lesions and visible blood vessels in the face. The FDA’s decision on Emrosi, which Journey developed in collaboration with Dr Reddy’s Laboratories, was based on positive results from two 16-week phase 3 rosacea trials, which met all co-primary and secondary endpoints, with no significant safety issues observed. The drug demonstrated statistically significant superiority over both Galderma’s standard-of-care Oracea 40mg capsules and placebo for Investigator’s Global Assessment treatment success as well as the reduction in total inflammatory lesion count. Beyond its physical manifestations, psychological impact has been recognised as a significant part of rosacea, with 90% of patients in National Rosacea Society surveys reporting that the condition had lowered their self-confidence and self-esteem, and 41% noting that it had caused them to avoid public contact or cancel social engagements. Additionally, among those with severe symptoms, 88% said the disorder had adversely affected their professional interactions, and 51% reported missing work because of their condition. Claude Maraoui, co-founder, president and chief executive officer of Journey Medical, said: “Rosacea is a difficult-to-treat skin condition and based on the favourable results from our phase 3 clinical trials, Emrosi has potential to become the best-in-class oral medication to treat the condition. “Our seasoned dermatology-focused sales force is now preparing for a successful launch and to establish Emrosi as a new standard of care in the treatment of rosacea.” Srinivas Sidgiddi, vice president, research and development at Journey Medical, added: “Emrosi showed great efficacy and tolerability in the pivotal clinical trials, and we are tremendously grateful to [everyone] who participated and contributed to this important approval milestone.” The company anticipates that an initial supply of the drug will be available late in the first quarter or early in the second quarter of 2025.